I've been trying to figure out the holes in their IBS/C IND it seems like a very good chance for approval. There is hyperphosphatemia Phase 3 data (though it seems likely they push back the data) at under cash (around net cash if factor in the debt) seems like a good speculative play.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.